Preterm Premature Rupture of Membrane

2

Review clinical trials related to Preterm Premature Rupture of Membrane. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)

To conduct an unblinded pragmatic randomized controlled trial (pRCT) "Improvement of PPROM Management with Prophylactic Antimicrobial Therapy (iPROMPT)" of a seven-day course of ceftriaxone, clarithromycin, and metronidazole versus the current standard of care of a seven-day course of ampicillin/amoxicillin and azithromycin or erythromycin to prolong pregnancy and decrease adverse perinatal outcomes among hospitalized pregnant individuals undergoing expectant management of PPROM \<34 weeks.

Participants needed: 56
Trial details
Phase: Phase 4Age: 18+Biological sex: FemaleType: InterventionalSponsor: Ohio State UniversityUpdated: Jan 27, 2026Locations: 2
Eligibility criteria

Admitted to the inpatient unit for expectant management of PPROM until delivery [+2]

Having received more than one dose of any prophylactic antibiotic [+3]

Status: Not yet recruiting

Selective Antibiotics When Symptoms Develop Versus Universal Antibiotics for Preterm Neonates

Preterm infants are born at less than 37 weeks of pregnancy. Sometimes a break or tear in the fluid filled bag that surrounds and protects the infant during pregnancy leads to an untimely birth. This state puts the infant at risk of serious condition called sepsis. Sepsis is a condition in which body responds inappropriately to an infection. Sepsis may progress to septic shock which can result in the loss of life. Doctors give antibiotics to treat sepsis. The goal of this research study is to find out: 1. Among neonates at risk of early-onset neonatal sepsis, whether a policy of administering antibiotics selectively to a subset of at-risk infants who later develop signs of sepsis is not inferior to administering antibiotics to all at-risk infants in the 1st week of life. 2. To find out if infants receiving selective antibiotics (as above) compared to those receiving antibiotics from birth (as above) require fewer antibiotic courses of 48 hours duration or more in the 1st week of life. 3. To find out whether infants receiving selective antibiotics (as above) compared to those receiving antibiotics from birth (as above) are significantly different with respect to a wide range of secondary outcomes (listed under "Outcomes").

Participants needed: 1,500
Trial details
Phase: Phase 3Age: 0-4Biological sex: AllType: InterventionalSponsor: Indian Council of Medical ResearchUpdated: Apr 22, 2024Locations: 1
Eligibility criteria

Gestational age of 26 to 34 weeks [+15]

Life-threatening congenital malformation [+7]